Skip to content
biosimilar development

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

  • Home
    • Home
  • About BR&R
  • Biosimilar Approval Status
  • BR&R Product Profiles
    • Abrilada
    • Amjevita
    • Avasola
    • Cyltezo
    • Erelzi
    • Eticovo
    • Fulphila
    • Hadlima
    • Herzuma
    • Hulio
    • Hyrimoz
    • Inflectra
    • Kanjinti
    • Mvasi
    • Nivestym
    • Nyvepria
    • Ogivri
    • Ontruzant
    • Renflexis
    • Retacrit
    • Ruxience
    • Trazimera
    • Truxima
    • Udenyca
    • Zarxio
    • Ziextenzo
    • Zirabev
  • Contact Us
  • The 2021 Biosimilars Market Report
  • $0.00 0 items

Cart

Your cart is currently empty.

Return to shop

Recent Posts

  • Biosimilars, Employers, Medicaid, and Rebates April 6, 2021
  • Mandatory Price Slashing After Biologic Exclusivity Expires: Much Lower Prices but at What Cost? March 23, 2021
  • NCCN Biosimilar White Paper Advocates Against Single Preferred Products by Payers March 19, 2021
  • Forcing Payers to Cover Biosimilars? Beware of Unintended Consequences March 10, 2021
  • Biosimilar Bytes for This Week February 12, 2021
  • Ophthalmology Biosimilars May Face a Formidable Challenger February 3, 2021
  • Section 1498 May Be a Potential Government Remedy for Approved, Unlaunched Etanercept Biosimilars January 28, 2021
  • Denosumab Biosimilar Competitors Gathering Data for February 2025 Launch January 20, 2021
  • An Oncologist’s Concern About the Biosimilar Use in Real-World Patients With Cancer December 31, 2020
  • Amgen Receives FDA Approval for Rituximab Biosimilar Riabni December 22, 2020

Recent Comments

Mandatory Price Slas… on New Proposal: Forget Biosimila…
Forcing Payers to Co… on Health Plans Still Utilize Fai…
Biosimilar Bytes for… on The Implications of Celltrion’…
Biosimilar Bytes for… on Ophthalmology Biosimilars May…
Ophthalmology Biosim… on Who Are the Key Lucentis Biosi…

Archives

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Top Posts & Pages

  • Biosimilar Approval Status
  • The Evolution of the Biosimilars Market
  • Who Are the Key Aflibercept Biosimilar Players to Watch?
  • Denosumab Biosimilar Competitors Gathering Data for February 2025 Launch
  • Who Are the Key Lucentis Biosimilar Players to Watch?
  • The Next-Generation Biosimilar Race: A Tale of Two Autoimmune Biologics
  • Apotex/Apobiologix: Success in Canada, but Are They Shelving Biosimilars in the US?
  • About BR&R
  • New Proposal: Forget Biosimilars, Move to Fixed Price Formulas
  • Ophthalmology Biosimilars May Face a Formidable Challenger
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

  • Twitter
  • LinkedIn
  • Home
  • About BR&R
  • Biosimilar Approval Status
  • Contact Us
  • Terms and Conditions

Copyright

Copyright 2013-2021 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.